AI Article Synopsis
- The study aimed to evaluate treatment patterns and healthcare resource use among patients with FLT3-mutated and FLT3-wild-type acute myeloid leukemia (AML) across 10 countries.
- Data was collected from medical charts of 1027 AML patients, revealing diverse treatment approaches based on FLT3 mutation status, age, and disease stage (newly diagnosed or relapsed/refractory).
- Results showed that FLT3 AML patients received more aggressive treatment compared to FLT3 wild-type patients, with significant healthcare resource utilization noted, especially after relapse or treatment failure.
Article Abstract
Objectives: To assess real-world treatment patterns and healthcare resource utilization (HRU) among patients with FLT3-mutated (FLT3 ) and FLT3-wild-type (FLT3 ) acute myeloid leukemia (AML).
Methods: Data were abstracted from medical charts of patients with AML from 10 countries. Patients were grouped based on their FLT3 mutation status, age (18-64 or ≥65), and whether they were newly diagnosed (ND) or relapsed/refractory (R/R).
Results: Charts of 1027 AML patients were included (183 FLT3 18-64 ND; 136 FLT3 ≥65 ND; 181 FLT3 R/R; 186 FLT3 18-64 ND; 159 FLT3 ≥65 ND; 182 FLT3 R/R). Substantial heterogeneity was observed in treatment patterns for AML. Among ND patients 18-64, the most common initial treatment was standard-to-intermediate dose cytarabine-based therapies (43.2% for FLT3 and 55.9% for FLT3 ); among ND patients ≥65, the most common initial treatment was hypomethylating agent-based therapies (36.0% and 47.2%). Among R/R patients, the most common initial treatment after R/R was best supportive care only (39.8% and 24.7%). HRU was substantial across cohorts during both event-free and post-event periods.
Conclusions: Treatment patterns of AML were heterogeneous and FLT3 AML was treated more aggressively than FLT3 disease. HRU was substantial for all cohorts, particularly after relapse or treatment failure.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6850763 | PMC |
| http://dx.doi.org/10.1111/ejh.13205 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Prevalence, aetiology and antimicrobial resistance profile of diabetic individuals suffering from community-acquired urinary tract infection.
J Med Microbiol
January 2025
Parul Institute of Applied Sciences, Faculty of Applied Sciences, Parul University, Vadodara, Gujarat 391760, India.
The rise in antimicrobial resistance poses a significant threat to global health, particularly among diabetic patients who are prone to urinary tract infections (UTIs). Pathogens that cause UTI among diabetic patients exhibit significant multidrug resistance (MDR) patterns, necessitating more precise empirical treatment strategies..
View Article and Find Full Text PDFBackground: Mental health remains among the top 10 leading causes of disease burden globally, and there is a significant treatment gap due to limited resources, stigma, limited accessibility, and low perceived need for treatment. Problem Management Plus, a World Health Organization-endorsed brief psychological intervention for mental health disorders, has been shown to be effective and cost-effective in various countries globally but faces implementation challenges, such as quality control in training, supervision, and delivery. While digital technologies to foster mental health care have the potential to close treatment gaps and address the issues of quality control, their development requires context-specific, interdisciplinary, and participatory approaches to enhance impact and acceptance.
View Article and Find Full Text PDFExpression Patterns of DLL3 Across Neuroendocrine and Non-Neuroendocrine Neoplasms Reveal Broad Opportunities for Therapeutic Targeting.
Cancer Res Commun
January 2025
University of Minnesota, Minnesota, MN, United States.
Neuroendocrine neoplasms (NENs) encompass a diverse set of malignancies with limited precision therapy options. Recently, therapies targeting DLL3 have shown clinical efficacy in aggressive NENs, including small cell lung cancers and neuroendocrine prostate cancers. Given the continued development and expansion of DLL3-targeted therapies, we sought to characterize the expression of DLL3 and identify its clinical and molecular correlates across diverse neuroendocrine and non-neuroendocrine cancers.
View Article and Find Full Text PDFA case of severe TBI: Recovery?
Appl Neuropsychol Child
January 2025
Department of Psychology and Neuroscience Center, Brigham Young University, Provo, USA.
Chronic stage neuropsychological assessments of children with severe TBI typically center around a referral question and focus on assessing cognitive, behavioral, and emotional functioning, making differential diagnoses, and planning treatment. When severe TBI-related neurological deficits are subtle and fall outside commonly assessed behavioral indicators, as can happen with theory of mind and social information processing, they can go unobserved and subsequently fail to be assessed. Additionally, should chronic stage cognitive, behavioral, and emotional assessment findings fall within the average to above average range, a child experiencing ongoing significant unassessed severe TBI-related subtle deficits could be mistakenly judged to have "recovered" from their injury; and to be experiencing no significant ongoing residual neurological deficits.
View Article and Find Full Text PDFPharmacological Aspects in the Management of Children and Adolescents with Prader-Willi Syndrome.
Paediatr Drugs
January 2025
Division of Endocrinology, Department of Pediatrics, University of Florida, PO Box 100296, Gainesville, FL, 32610, USA.
Prader-Willi syndrome is a rare neurodevelopmental disorder that impacts the musculoskeletal, endocrine, pulmonary, neurologic, ocular, and gastrointestinal systems. In addition, individuals with Prader-Willi syndrome have issues with cognitive development, characteristic behavioral problems, and perhaps most profoundly, appetite control. Currently, the only US Food and Drug Administration-approved therapy for Prader-Willi syndrome is growth hormone, which has been Food and Drug Administration approved for > 20 years for the treatment of growth failure in Prader-Willi syndrome.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!